Advanced human brain organoids for modeling patient response in neurodegeneration (ABROND)

Important results from the project

The project achieved its core goals of building a strong consortium, refining the disease use case, and developing a competitive Horizon Europe proposal. Strategic partnerships were established across academia, industry, and regulatory stakeholders. New regulatory interactions, including with EMA, and reusable proposal assets further strengthened future development opportunities.

Expected long term effects

The project supports the adoption of human-based organoid technologies to enable faster, more predictive drug development. It contributes to establishing regulatory pathways for NAMs and setting new industry standards. Long term, this can accelerate delivery of innovative therapies, particularly in high unmet need areas like neurological disorders.

Approach and implementation

The project was executed within allocated time and according to the planned three work packages: consortium building, scientific and regulatory concept development, and proposal preparation. An external factor was the change in final consortium composition, which led to a shift in disease focus. This was an unplanned but strategic adjustment that strengthened alignment with partner expertise without affecting the overall objectives.